Oxidative Medicine and Cellular Longevity

Oxidative Medicine and Cellular Longevity / 2020 / Article
Special Issue

Antioxidants and Prooxidants: Effects on Health and Aging 2020

View this Special Issue

Research Article | Open Access

Volume 2020 |Article ID 9834742 | https://doi.org/10.1155/2020/9834742

Klara Zubčić, Vedrana Radovanović, Josipa Vlainić, Patrick R. Hof, Nada Oršolić, Goran Šimić, Maja Jazvinšćak Jembrek, "PI3K/Akt and ERK1/2 Signalling Are Involved in Quercetin-Mediated Neuroprotection against Copper-Induced Injury", Oxidative Medicine and Cellular Longevity, vol. 2020, Article ID 9834742, 14 pages, 2020. https://doi.org/10.1155/2020/9834742

PI3K/Akt and ERK1/2 Signalling Are Involved in Quercetin-Mediated Neuroprotection against Copper-Induced Injury

Academic Editor: Márcio Carocho
Received26 Mar 2020
Accepted12 Jun 2020
Published11 Jul 2020

Abstract

Copper, a transition metal with essential cellular functions, exerts neurotoxic effects when present in excess by promoting production of reactive oxygen species (ROS). The aim of the present study was to investigate potential benefits of flavonoid quercetin against copper-induced toxicity. Results obtained with MTT assay indicate that the effects of quercetin are determined by the severity of the toxic insult. In moderately injured P19 neuronal cells, concomitant treatment with 150 μM quercetin improved viability by preventing ROS formation, caspase-3 activation, and chromatin condensation. Western blot analysis revealed that quercetin reduced copper-induced increase in p53 upregulated modulator of apoptosis (PUMA) expression and promoted upregulation of nucleoside diphosphate kinase NME1. Levels of p53 and Bax proteins were not affected by both copper and quercetin. UO126 and wortmannin, inhibitors of ERK1/2 and PI3K/Akt signalling pathways, respectively, prevented neuroprotective effects of quercetin. In severely injured neurons, 30 μM quercetin exerted strong prooxidative action and exacerbated cytotoxic effects of copper, whereas 150 μM quercetin failed to affect neuronal survival. These results demonstrate the dual nature of quercetin action in copper-related neurodegeneration. Hence, they are relevant in the context of considering quercetin as a possible therapeutic for neuroprotection and imply that detailed pharmacological and toxicological studies must be carried out for natural compounds capable of acting both as antioxidants and prooxidants.

1. Introduction

Neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’ disease, are chronic and progressive disorders characterized by slow degeneration of neurons and ultimately cell death. Structural changes disable proper neuronal functioning in affected brain areas and result in the functional deficits characteristic for these diseases [1]. As ageing is the main risk factor for their development, they represent a significant medical and socioeconomic problem worldwide. Despite progress into the understanding of the complex network of molecular and cellular mechanisms that underlie the development of these devastating conditions, no effective pharmacological approaches are yet capable of delaying their onset and slowing down progression [2].

Compelling data suggest that oxidative stress is one of the pivotal factors contributing to the common pathophysiology of neurodegenerative diseases [3, 4]. Oxidative stress occurs when increased accumulation of reactive oxygen species (ROS) overwhelms the brain’s intrinsic capacity of oxidative defence, leading to detrimental effects on neuronal functioning and viability. Due to several reasons, including the presence of redox active transition metals, the brain is particularly vulnerable to oxidative injury [5]. Copper is an essential transition metal required for catalytic activity of many brain proteins that are involved in various biological processes, such as respiration, antioxidant activity, catecholamine biosynthesis, and myelin formation [6, 7]. However, if present in excess, unbound copper ions may initiate redox cycling reactions, promote production of ROS, and create an oxidative environment capable of modifying the structure and function of biological macromolecules, thus threatening the functionality and viability of brain cells. In the presence of biological reductants, Cu2+ can be reduced to Cu+ that via the Fenton-catalysed Haber-Weiss reaction may drive the generation of extremely toxic hydroxyl radicals, the most dangerous ROS in biological systems [8].

Dysregulation of copper homeostasis, which results in altered redox balance and intracellular redox signalling, is increasingly recognized as an important factor in pathological processes underlying neurodegeneration [9, 10]. Despite some conflicting findings, it seems that serum copper levels are elevated in patients with Alzheimer’s disease [11, 12]. Besides a copper-induced increase in ROS generation and the accompanying oxidative stress, aberrant copper/protein interactions may also contribute to copper toxicity and progression of the diseases [8, 13]. Thus, in contrast to healthy conditions, copper binds to amyloid β (Aβ) protein specifically in Alzheimer’s disease. Cu2+ binding to Aβ increases its ability to form ubiquitin-containing aggregates and greatly promotes Aβ-induced generation of ROS [10, 14, 15]. Copper also may compromise the activity of some proteolytic enzymes involved in a degradation of Aβ aggregates. It can directly interact with metal ions essential for the catalytic and structural properties of metalloproteinases, and can confer higher proteolytic resistance to aggregated Aβ species [15]. Furthermore, copper ions promote tau hyperphosphorylation and stimulate its self-aggregation into paired helical filaments in vitro [16]. Regarding Parkinson’s disease, copper increases α-synuclein oligomerization, whereas increased expression of α-synuclein enhances neuronal susceptibility to copper toxicity [17]. Copper also prevents the ubiquitination of protein substrates and impairs the proteolytic activity of the ubiquitin-proteasome system, the main pathway for the elimination of the misfolded proteins. Moreover, divalent copper decreases the thermal stability of ubiquitin and promotes its aggregation into spherical particles, probably compromising the neuroprotective function of the ubiquitin-proteasome system [15]. Thus, maintaining copper homeostasis could be considered as an essential prerequisite for the preservation of brain health and proper functioning of neural networks.

Flavonoids represent one of the main groups of bioactive polyphenolic phytochemicals in human diet and are commonly associated with neuroprotection [2, 18]. They can reduce the risk of developing neurodegenerative pathologies, rescue neurons from various forms of toxin-induced neuronal death in vitro, suppress neuroinflammation, improve vascular function and cerebral blood flow, and enhance cognitive abilities [2, 19]. The molecular mechanisms underlying the beneficial effects of flavonoids on diverse brain pathologies are primarily attributed to their antioxidant activity (through direct free radical scavenging, induction of endogenous antioxidative defence, and chelation of metal catalysts) and modulation of intracellular signalling pathways involved in neuronal death or survival [2, 18, 20, 21]. In view of their multiple targets and mechanisms of action, various flavonoids became increasingly appreciated as promising candidates for the development of novel and relatively safe therapeutic options in oxidative stress-induced neurodegeneration, particularly in conditions with deregulated metal homeostasis [18, 22].

Quercetin (3,3,4,5,7-pentahydroxyflavone) is one of the most abundant natural flavonoids and one of the most potent scavengers of ROS due to its double bonds and hydroxyl groups that stabilize free radicals [23] (Figure 1). Key structural features for scavenging activity are the catechol structure in the B ring, the enol moiety and the 4-keto group in the C ring, and the 5-OH group in the A ring [24].

Similar to other flavonoids, the neuroprotective effects of quercetin against oxidative stress-mediated toxicity have been reported on some types of neuronal cells and assigned to its antioxidant, antiapoptotic, and signal transduction-modifying properties [2528]. The biological effects of quercetin are also influenced by the presence of metal ions as hydroxy and oxo groups present in the polyphenolic quercetin structure may form complexes with various metal ions [29, 30]. However, although quercetin may inhibit apoptosis and prevent death in some nontumorigenic cells, it may also exert direct proapoptotic effects on tumour cells [31, 32]. Furthermore, depending on the dose, it may exert antioxidative as well as prooxidative effects [33]. Chelation of transition metals is one of the most important mechanisms of the antioxidative action of quercetin. Through metal chelation, quercetin may prevent Fenton’s reaction and subsequent ROS generation. In addition, in a stable chelation complex, quercetin exhibits a more powerful antioxidative effect as the scavenging activity of the complex is higher than for quercetin alone [34]. Formation of the complex depends on the metal : ligand ratio and the solvent used. Copper and quercetin may form complexes with copper-to-ligand ratios of 1 : 1, 2 : 1, 1 : 3, and 1 : 2. The 1 : 1 complex is particularly prominent in the presence of excess copper [34]. Metal coordination may occur via a carbonyl oxygen in the C ring and nearby hydroxyl groups (3-OH or 5-OH) in the A or C rings, and between the ortho-hydroxyl groups in the B ring [34]. The site between the 5-OH group and the 4-oxo group may be the most important [35]. The estimated binding constant of the irreversible complexation reaction is at pH 7.4 [36]. Following complexation, quercetin is rapidly autooxidized and forms quinone radicals and/or quinone intermediates that mediate prooxidative effects. The other mechanism that contributes to the prooxidative activity of quercetin is its ability to reduce divalent copper to Cu(I). Thus, the cytotoxic effects of quercetin may be explained not only by the increase in ROS production but also by the production of highly oxidant and electrophilic oxidation products [29, 36]. A schematic representation of the antioxidative and prooxidative activities of quercetin is shown in Figure 1.

In this context, the aim of the present study was to investigate the effects of quercetin against copper-induced toxicity in P19 neurons to understand better the mechanistic interactions between, and cellular response to, concomitant treatment with natural antioxidants and potentially toxic metals. Ultimately, this might be useful for the improvement of therapeutic options in copper-driven neurodegenerative changes.

2. Materials and Methods

2.1. Chemicals

All-trans-retinoic acid (ATRA), cytosine-arabinofuranoside (AraC), 1,4-diamino-2,3-dicyano-1,4-bis(2-aminophenylthio)-butadiene (UO126), 2,7-dichlorofluorescin diacetate (DCF-DA), 3-(4,5-dimethylthiazol-2yl)2,5-dyphenyl-2H-tetrazolium bromide (MTT), and Hoechst 33342 were purchased from Sigma-Aldrich (St. Louis, MO, USA). All chemicals used for the maintenance and differentiation of P19 cells, including culture medium (Dulbecco’ Modified Eagle’s Medium, DMEM), foetal bovine serum (FBS), trypsin, antibiotics, L-glutamine, and an insulin-transferrin-selenium-ethanolamine (ITS-X) supplement were purchased from Sigma-Aldrich (St. Louis, MO, USA) or Gibco (Paisley, UK). Wortmannin was purchased from Ascent Scientific (Princeton, NJ, USA). Copper sulfate pentahydrate was obtained from Kemika (Zagreb, Croatia). All other chemicals used were of analytical grade.

2.2. P19 Cell Culturing and P19 Neuronal Differentiation

Undifferentiated P19 cells (a pluripotent mouse embryonal carcinoma cell line) were kindly provided by J. Pachernik (Prague, Czech Republic). They were cultured in high-glucose DMEM containing 10% heat-inactivated FBS, 2 mM L-glutamine, 100 units/ml penicillin G, and 100 μg/ml streptomycin (growth medium) in a humidified atmosphere of 5% CO2 at 37°C. They were passaged every two days.

Neuronal differentiation of P19 cells was induced by exposure to 1 μM all-trans-retinoic acid (ATRA) for 4 days. Exponentially growing P19 cells () were seeded into 10 cm bacteriological grade Petri dishes containing 10 ml of DMEM medium supplemented with a reduced concentration of FBS (5%), 2 mM L-glutamine, and antibiotics (induction medium). ATRA is added immediately after plating. Aggregates (embryonic bodies) of P19 cells were formed after 1-2 days. After 48 h, the old medium was replaced with the fresh ATRA-containing medium and aggregated cultures were grown for an additional two days.

After the 4-day ATRA treatment, P19 embryonic bodies were harvested, washed with phosphate-buffered saline (PBS), dissociated by trypsinization and pipetting, collected by centrifugation (1,250 rpm, 5 min), and finally resuspended in growth medium. For optimal neuronal differentiation, single cells at a density 105 cells/cm2 were plated onto 96-well plates or 35 mm Petri culture dishes (Sarstedt, Newton, NC, USA and Nunc A/S, Roskilde, Denmark) and grown in growth medium for two days. Finally, the growth medium was changed to serum-free medium containing DMEM supplemented with an ITS-X solution containing insulin, transferrin, selenium and ethanolamine solution (Gibco), 0.5 mM L-glutamine, and antibiotics (neuron-specific medium) and cells were grown for 2 more days in the presence of 10 μM of the mitotic inhibitor AraC to inhibit proliferation of nonneuronal cells. Complete neuronal differentiation was confirmed with monoclonal anti-tubulin β-III mouse IgG, clone TU-20 conjugated with Alexa Fluor 488 (Millipore, Temecula, CA), see Supplementary Material, Figure S1. At the end of differentiation procedure, P19 neurons exert morphological, neurochemical, and electrophysiological properties resembling neurons from the mammalian brain, and represent an established model for pharmacological studies [25, 26, 37].

2.3. Drug Treatment

In all experiments, P19 neurons were treated for 8 days from the initiation of differentiation (DIV8). Each batch of cultured cells was divided into control and drug-treated groups. For inducing oxidative damage, P19 neurons were incubated with 0.5 or 1 mM CuSO4 in the neuron-specific medium for 24 hours, alone or in the presence of various concentrations of quercetin. All selected concentrations of quercetin did not modify the viability of P19 neurons when applied alone [25, 38]. To examine the effects of quercetin on the activation of the signalling pathways of phosphatidylinositol-3-kinase (PI3K)/Akt and extracellular signal-regulated kinases 1/2 (ERK1/2), P19 neurons were pretreated with wortmannin and UO126, respectively. Wortmannin is a nonspecific, covalent inhibitor of PI3K, an upstream activator of Akt. Wortmannin (30 nM) and UO126 (10 μM) were present 60 min prior and during the exposure to 0.5 mM copper and 150 μM quercetin. The concentrations were chosen based on our preliminary experiments. We selected the smallest concentrations of inhibitors that modified the neuroprotective effect of quercetin but did not affect neuronal viability when applied alone.

2.4. Assessment of Neuronal Viability

Survival of P19 neurons was assessed by using colorimetric MTT assay. Cell viability was estimated according to the ability of P19 neurons to cleave MTT to an insoluble formazan product due to the activity of mitochondrial dehydrogenases. At the end of the incubation period, 40 μl of MTT solution prepared in neuron-specific medium (final concentration 0.5 mg/ml) was added to each well and incubated for 3 h at 37°C. Precipitated formazan was dissolved by adding 160 μl of dimethyl sulfoxide (DMSO). The absorbance of each well was recorded by an automatic microplate reader at 570 nm. After blank subtraction from all absorbance readings, cell survival was expressed as the percentage of absorbance of quercetin- and copper-treated cells relative to that of untreated control cells.

2.5. Measurement of Intracellular ROS Accumulation

Intracellular production of ROS as a measure of cellular oxidative stress was detected using the cell permeable substrate DCF-DA. This fluorogenic probe is widely used for monitoring cellular oxidative activity. DCF-DA diffuses into the cells and becomes hydrolysed to nonfluorescent 2,7-dichlorofluorescin by intracellular esterases. Accumulated 2,7-dichlorofluorescin reacts with intracellular ROS and forms the highly fluorescent compound dichlorofluorescein (DCF). The method is reliable and efficient for evaluating the potency of prooxidants as well as the efficacy of antioxidants against oxidative stress and is suitable as a marker for the total ROS production [39]. Following treatment, P19 neurons were incubated with 100 μM DCF-DA in PBS for 1 h in darkness, rinsed, and incubated for an additional 1 h in PBS. Oxidation of DCF-DA to DCF was determined using the Varian Cary Eclipse Fluorescence Spectrophotometer (Varian Optical Spectroscopy Instruments, Mulgrave, Victoria, Australia) with an excitation wavelength () of 504 nm and an emission wavelength () of 529 nm. The results were expressed as the percentage of fluorescence intensity obtained in the control group.

2.6. Determination of Reduced Glutathione (GSH) Levels

GSH is one of the major nonenzymatic antioxidants present in neuronal cells. We monitored changes in GSH levels with the luminescence-based GSH-Glo Glutathione Assay (Promega, Madison, WI, USA) according to the manufacturer’s instructions. Briefly, the assay couples two chemical reactions. The first reaction is the conversion of a luciferin derivative into luciferin, which is catalysed by glutathione-S-transferase. In the second reaction catalysed by firefly luciferase, the amount of luciferin produced is detected as a luminescent signal. The intensity of the signal is proportional to the GSH content. At the end of exposure to copper and quercetin, the medium was removed and 100 μl of the GSH-Glo reagent was added in each well. The samples were incubated for 30 min at RT. Thereafter, 100 μl of the luciferin detection reagent was added to each well, mixed briefly, and incubated for a further 15 minutes. Emitted light was quantified by the Fluoroskan Ascent FL luminometer (Thermo Fisher Scientific).

2.7. Determination of Caspase-3/7 Activity

Caspase-3/7 activity was monitored by using the Apo-ONE Homogeneous Caspase-3/7 Assay (Promega, Madison, WI, USA). These two members of the caspase family are the key effector enzymes in caspase-dependent apoptosis. To perform the assay, the cell permeabilization buffer and nonfluorescent caspase substrate Z-DEVD-rhodamine 110 were mixed (50 μl) and added directly to P19 neurons treated with quercetin and copper in 50 μl of culture medium. The sample was shaken for 5 min and incubated at RT in the dark for 4 h. Cleavage of the DEVD peptides by activated caspase-3/7 releases rhodamine 110, which becomes intensely fluorescent after excitation. The amount of generated fluorescent product is proportional to the amount of caspase-3/7 cleavage activity in each sample. The emitted fluorescence was recorded on a plate reader (Fluoroskan Ascent FL, Thermo Fisher Scientific) at an excitation wavelength of 485 nm and an emission wavelength of 538 nm.

2.8. Determination of Nuclear Changes by Hoechst Staining

Hoechst 33342 staining was used to examine nuclear condensation in P19 neurons exposed to copper and quercetin. Following treatment, attached and floating cells were collected, centrifuged at 250 g, resuspended in 50 μl of culture medium, and stained with 5 μM Hoechst 33342 for 10 min at RT. Cells were analyzed under a fluorescent microscope. Cells with bright blue nuclei were counted. The percentage of cells with condensed nuclei in relation to the total number of cells was determined by counting at least 500 neurons.

2.9. Western Blot Analysis of p53, Bax, PUMA, and NME1/2 Protein Expression

The expression of proteins was analyzed in total cell extracts. Following treatment, P19 neurons grown in 25 cm2 flasks were washed twice with PBS, lysed by scrapping into 100 μl of RIPA buffer (Sigma-Aldrich, St. Louis, MO, USA) containing protease inhibitors (cOmplete, Mini, EDTA-free Protease Inhibitor Cocktail Tablets; Roche, Indianapolis, IN, USA), and sonicated. The protein concentration was determined using the Pierce BCA Protein Assay Kit (Thermo Fisher Scientific, Waltham, MA, USA). A standard curve was developed using a series of bovine serum albumin dilutions in the 100 μg/ml to 1500 μg/ml range, and a linear plot of concentration vs. absorbance (at 570 nm) was generated to determine protein concentration in different samples. Extracted proteins were resolved using SDS-PAGE and analyzed by immunoblotting on nitrocellulose membranes (Whatman, GE Healthcare Life Sciences, Berlin, Germany). Nonspecific binding was blocked by 5% nonfat milk in Tris-buffered saline containing 0.05% Tween 20 (TBST) for 1 h at RT. Immunoblots were incubated overnight with a primary antibody and then for 2 h at RT by an appropriate secondary antibody. Blots were incubated with the primary anti-p53 antibody (clone Pab 1801: sc-98 and Pab 240: sc-99, Santa Cruz Biotechnology, 1 : 500; clone Pab 421, kindly provided by Prof. J.-C. Bourdon, Dundee, United Kingdom, 1 : 200), anti-PUMAα/β antibody (G-3, sc-374223, Santa Cruz Biotechnology, 1 : 500), anti-Bax antibody (B-9: sc-7480, Santa Cruz Biotechnology, 1 : 500), and anti-NME1/NME2 antibody (kindly provided by Drs. I. Lascu, Bordeaux, France, and S. Volarević, Rijeka, Croatia, 1 : 3000). The anti-β-actin antibody (AC-15, Sigma-Aldrich, 1 : 5000) was used for normalization. Immunoreactive bands were visualized by chemiluminescence detection (Western Lightning Plus-ECL, Enhanced Chemiluminescence Substrate, PerkinElmer, Waltham, MA, USA) of an HRP-labelled secondary antibody (anti-mouse IgG, GE Healthcare, ECL mouse IgG, 1 : 5000) and anti-rabbit IgG (Cell Signaling Technology, 1 : 3000) and quantified by using ImageJ NIH software after detection with Alliance 4.7 (UVItec Cambridge, London, UK).

2.10. Statistical Analysis

Statistical analyses of the data were carried out using GraphPad Software (San Diego, CA). All values are represented as (SD). Comparisons between group means were evaluated by one-way ANOVA, and when statistically significant, post hoc analysis with Dunnett’s multiple comparison test or Tukey’s test followed. Data on samples fit assumptions for ANOVA (dependent variable is continuous, observations are independent, there are no significant outliers, dependent variable is approximately normally distributed for each of the independent variables, and independent variable combinations pass Levene’s test for homogeneity of variances). The statistical significance level was set at .

3. Results

3.1. Effects of Copper and Quercetin on Viability of P19 Neurons

As previously published [40], exposure to increasing concentrations of copper reduced the viability of P19 neurons. Treatment with 0.5 mM CuSO4 for 24 h induced moderate cell death (neuronal viability was decreased by 35%), whereas exposure to 1 mM CuSO4 induced more pronounced reduction of neuronal survival and approximately doubled the number of dead cells. We investigated the effects of three different concentrations of quercetin (3, 30, and 150 μM) on copper-induced neuronal death. These concentrations of quercetin did not induce apparent changes in neuronal viability when applied alone [38]. As presented in Figure 2(a), in P19 neurons simultaneously exposed to 0.5 mM CuSO4 and quercetin, the highest concentration of quercetin exerted a neuroprotective effect and improved neuronal survival, although neuronal viability was not completely returned to the control value of the vehicle-treated group (87.5% of the control group, ). Conversely, when quercetin was applied in the presence of 1 mM CuSO4, a decrease in neuronal survival was obtained with 30 μM quercetin (neuronal viability was further decreased by 48% in comparison with the group exposed solely to 1 mM CuSO4), while treatment with 3 or 150 μM quercetin did not modify the effects of copper (Figure 2(b)).

3.2. The effects of Quercetin against Copper-Induced Neuronal Death Are Related to ROS Generation

Copper ions upregulated intracellular ROS generation in a dose-dependent manner ( and vs. control; one-way ANOVA followed by Dunnett’s test, Figure 3). In mild oxidative conditions induced by exposure to 0.5 mM CuSO4, 3 and 30 μM quercetin did not affect ROS amounts, while the presence of 150 μM quercetin preserved ROS production at the physiological levels, indicating an antioxidative mode of quercetin action at this concentration (Figure 3(a)). In a highly oxidative environment (Figure 3(b)), 3 and 150 μM concentrations were without effects, whereas 30 μM quercetin upregulated ROS production (62.8%, ), suggesting a prooxidative mechanism of its action. Interestingly, in severe oxidative stress, 150 μM quercetin also tended to decrease ROS production. It reduced ROS levels by 39.6% in comparison to copper-treated cells (from 557.9 to 336.9 of relative fluorescence units (RFU)), although this reduction was not statistically significant. Similarly, a small although insignificant increase of ROS (18.2%, from 151.9 to 179.6 RFU) was observed for 30 μM quercetin in mild oxidative conditions.

Alterations in ROS production may affect levels of GSH, the most important endogenous mechanism of nonenzymatic antioxidative defence. As previously reported, exposure to divalent copper ions depleted GSH content in neuronal cells in a dose-dependent manner [40]. In this study, 150 μM quercetin induced a further decrease in GSH levels in mild oxidative stress conditions, whereas in P19 neurons treated with 1 mM CuSO4, the GSH-reducing effect was observed for 30 and 150 μM concentrations (Figure 3(c)).

3.3. Quercetin Prevents Copper-Induced Changes in Chromatin Condensation and Decreased Caspase-3/7 Activity

ROS may be an initiating factor in triggering caspase-dependent and caspase-independent neuronal deaths that are both characterized by nuclear changes in the form of chromatin condensation [41]. However, the effects of flavonoids on cell viability may also result from the inhibition of the activity of the executioner caspases-3/7 in the classical apoptotic pathway or may be independent on caspase activity [25, 42]. To distinguish between these two possibilities, we monitored caspase-3/7 activity and chromatin density. As shown in Figure 4(a), in P19 neurons exposed to both 0.5 mM and 1 mM CuSO4, 150 μM quercetin completely prevented a copper-induced increase in caspase-3/7 activation. In mild oxidative stress, 30 μM quercetin did not modify caspase-3/7 activity, while in a highly oxidative environment, this concentration of quercetin further exacerbated copper-induced enhancement of caspase-3/7 activation. The intensity of chromatin condensation was evaluated by staining with the fluorescent DNA dye Hoechst 33342. In copper-treated P19 neurons, the intensity of DNA staining with Hoechst 33342 was significantly increased. The number of nuclei with condensed chromatin was increased by 90% and 189% following exposure to 0.5 mM CuSO4 and 1 mM CuSO4, respectively, and this effect on the increase in chromatin density was more pronounced than the effect on caspase-3/7 activity. Concomitant treatment with 150 μM quercetin completely prevented changes of chromatin morphology in both copper-treated groups, whereas exposure to 30 μM quercetin and 1 mM CuSO4 did not further promote copper-induced changes in chromatin condensation (Figure 4(b)).

3.4. Quercetin Prevents Copper-Induced Upregulation of PUMA Expression and Upregulates Expression of NME1 Protein

To elucidate the molecular mechanisms of the neuroprotective action of quercetin further, we monitored changes in the expression of proteins involved in the regulation of neuronal death cascade and whose expression is typically modified in oxidative conditions. As quercetin at 3 and 30 μM concentrations did not modify neuronal survival and ROS formation, we assessed changes induced only by 150 μM quercetin. Transcription factor p53 plays an important role in determining neuronal death or survival by coordinating transcription of pro- and antioxidative proteins and through the regulation of mitochondrial metabolism and ROS production [43]. However, by using three different p53 antibodies, we found no copper- or quercetin-induced changes in p53 levels. The same result was obtained for Bax, a downstream target of p53. However, expression of PUMA, an important regulator of neuronal apoptosis, was highly upregulated by 0.5 mM CuSO4. This increase in PUMA expression was reduced in P19 neurons concomitantly treated with quercetin. We also monitored changes in the expression of nucleoside diphosphate kinase NME1. In response to environmental stimuli, this enzyme can translocate to the nucleus and regulate transcription and DNA repair [44]. Although expression of NME1 protein was not significantly altered in P19 neurons treated with 0.5 mM CuSO4 alone, NME1 gene expression was enhanced by 69% in the presence of 150 μM quercetin (Figure 5).

3.5. The Neuroprotective Effect of Quercetin Is Mediated through the Modulation of Akt and ERK1/2 Signalling Pathways

To investigate whether neuroprotective effects were mediated through the modulation of intracellular signalling, we treated P19 neurons concomitantly with copper, quercetin, and inhibitors of the Akt and ERK signalling pathways. Wortmannin is a specific, covalent inhibitor of PI3K. Akt/PKB is located downstream of PI3K and, therefore, functions as part of a wortmannin-sensitive signalling pathway. UO126 is a highly selective inhibitor of mitogen-activated protein kinase kinase MEK1/2 that further activates ERK1/2 by phosphorylation at Thr and Tyr residues [45]. Our results indicate that the neuroprotective effect of quercetin was mediated through the activation of Akt and ERK1/2 signalling as the prosurvival effect of quercetin was no longer visible in the presence of wortmannin (Figure 6(a)) and UO126 (Figure 6(b)).

4. Discussion

Deregulation of metal homeostasis, accompanied by enhanced production of free radicals and increased oxidative stress, is directly involved in the onset and progression of neurodegenerative diseases (for reviews, see [13, 46]). Natural antioxidants have potential to reestablish redox homeostasis and reduce or prevent metal-induced oxidative damage [4749]. Besides their ability to act as antioxidants, metal chelators, and modulators of intracellular signalling, flavonoids may inhibit the formation of Aβ fibrils [50, 51] and improve the activity of the ubiquitin-proteasome system [52, 53]. Hence, flavonoids, including quercetin, represent a promising multitarget drug option, particularly if applied during the early stage of neurodegenerative processes. Accordingly, a few dietary intervention studies have demonstrated an ability of phytochemicals to improve neurological dysfunction [54]. We studied the effects of quercetin, one of the most abundant flavonoids from human diet, against copper-initiated neuronal death. Previous studies indicated that Cu2+-induced oxidative injury can be attenuated by polyphenols [6, 55]. Our results suggest that the effects of copper and quercetin on neuronal survival could be governed by their concentrations and are dependent on the severity of toxic insult. In mild oxidative stress, quercetin may exert a desirable neuroprotective action and improve neuronal survival. However, in severely damaged neurons, quercetin, applied at specific dose, is capable of exacerbating the toxic effect of copper leading to more pronounced neuronal death. The dual effects of quercetin on cell viability were also observed in other studies [33, 56].

The toxic effects of copper are mostly attributed to its role in oxidative stress induction and downstream death events [27, 57]. Hence, the prevention of ROS production might be a promising strategy against copper-induced toxicity and neurodegeneration in general [58]. We previously demonstrated that quercetin applied alone attenuated the generation of radical species in P19 neurons [38]. However, monitoring ROS production in the presence of copper ions revealed the antioxidative as well as prooxidative effects of the polyphenolic structure of quercetin, in a manner related to its effects on neuronal viability. In copper-induced mild oxidative stress, the neuroprotection offered by quercetin was associated with its antioxidative properties, while its prooxidative ability largely contributed to increasing neuronal death in severe oxidative stress. In P19 neurons exposed to low and high concentrations of hydrogen peroxide, quercetin exhibited only an antioxidative action [25], pointing out to the contribution of copper ions in its prooxidative action.

Additional studies also demonstrated that the effects of quercetin in the presence of copper ions are dose-dependent and related to the intensity of oxidative processes [5961]. They also pointed out that the mechanisms of quercetin/copper interactions are rather complex and worth studying further. It has been shown that quercetin induces oxidative DNA damage at specific sites in the presence of Cu(II); however, with high doses of quercetin, DNA damage is decreased [59]. In another study, quercetin at low Cu2+ concentrations protected from DNA damage, whereas quercetin at higher Cu2+ concentrations promoted DNA cleavage [60]. By measuring the extent of lipid peroxidation on low-density lipoprotein preparations, Filipe et al. [61] reported that quercetin at high Cu2+ concentrations decreased lipid peroxidation. In the presence of low Cu2+ concentrations, quercetin exhibited a dual effect acting as a prooxidant at low concentration and exerting antioxidant activity when applied at high concentrations. Flavonoids exert their antioxidative action via various mechanisms including direct ROS trapping, prevention of peroxidation, inhibition of ROS-producing enzymes, and chelation of transition metals [34]. Regarding the chelation process, interactions between quercetin and copper(II) are promoted in the presence of excess copper, and the copper-quercetin complex is a better free radical acceptor than quercetin alone [30, 34]. However, in the presence of metal ions, natural antioxidants may switch their biological effects to prooxidant activity. Several studies investigating the interactions between quercetin and copper ions in different conditions in vitro demonstrated the prooxidative nature of their interplay. For example, quercetin undergoes a slow autooxidation under physiological pH, producing hydrogen peroxide. In the presence of copper, it is more prone to autooxidation, and accordingly generates more hydrogen peroxide [36]. In the presence of Cu2+, phenolic compounds such as quercetin are oxidized to a semiquinone radical. The semioxidized quercetin is not stable and undergoes a second oxidation reaction that yields ortho-quinone and superoxide anion (O2). The superoxide anion reacts with catalytic Cu+ and forms hydrogen peroxide that is further converted into a hydroxyl radical (OH) promoting formation of more ROS [62]. However, even the prooxidant activity of quercetin may stimulate a cellular defence response by activating redox-dependent signal transduction pathways leading to the upregulation of antioxidative enzymes [63]. As suggested by Filipe et al. [61], it is likely that prooxidative and antioxidative mechanisms are operative simultaneously, but at certain combinations of copper and quercetin concentrations, one of the mechanisms prevails, determining the overall effect on neuronal viability.

The main oxidized metabolite of quercetin, quercetin-quinone, exerts specific reactivity towards thiol groups which may lead to the loss of protein functions and jeopardize neuronal functioning [64]. At first, quercetin preferentially reacts with GSH; however, at depleted GSH levels, it reacts with protein thiols, forming relatively stable adducts [64]. In our study, the overall effect on GSH content was not consistent with neuronal survival. Quercetin applied at a concentration of 150 μM exacerbated the copper-induced decrease of the GSH content in both mild and severe oxidative stress. GSH levels were similar in neurons exposed to 1 mM CuSO4 alone (viability of 35% in comparison to the control group) and in neurons exposed to 0.5 mM CuSO4 and 150 μM quercetin (viability of 88% in comparison to the control group). This indicates that downstream effects of ROS on neuronal death pathways and signalling cascades, rather than protein dysfunctions due to the formation of thiol adducts, determine the overall impact on neuronal viability.

Upregulation of ROS levels is usually accompanied with the activation of executioner caspases-3/7, particularly in a mildly oxidative environment [65]. In severe oxidative injury characterized by a prominent decrease in neuronal viability, neuronal cells also die by necrosis [25]. Our study shows that copper induces caspase-3/7 activation in a dose-dependent manner. Treatment with 0.5 mM CuSO4 induced a very small (27%), statistically significant increase, whereas effects of 1 mM CuSO4 were more than doubled. Structural changes of chromatin are much more pronounced than the effect on caspase-3/7 activity with exposure to CuSO4. As condensed nuclei are a hallmark of both caspase-dependent and caspase-independent cell death, we suggest that in mild oxidative stress, neuronal cells predominantly died by a caspase-independent mechanism, but that in a highly oxidative environment, the classic apoptotic machinery is triggered, together with necrotic death, as the number of dead cells exceeded the number of dead cells with chromatin changes [40]. Nevertheless, effects of quercetin on copper-induced enzymatic and nuclear changes were in a good correlation with the overall effect of quercetin on neuronal viability.

Transcription factor p53 may play an important role in determining cell death or survival by guiding cellular response to diverse genotoxic challenges, including oxidative stress, primarily by regulating transcription of various pro- and antiapoptotic genes [43]. Bax is another common effector of cell death. In response to various stress stimuli, it translocates to the mitochondria and induces membrane permeabilization, enabling the release of various proapoptotic effectors [66]. However, in our conditions, the levels of p53 and Bax remained stable. Previous studies have shown that Bax translocation, rather than its upregulation, could be the crucial event for initiating neuronal death after exposure to various agents that increase production of ROS [67]. As for Bax, it is possible that p53 translocation, instead of p53 upregulation, is the most important factor for the initiation of death events at this concentration of copper [68, 69]. However, quercetin also did not modify expression of either p53 or Bax indicating that these proteins did not contribute to the prosurvival effect of quercetin.

PUMA is a potent inducer of p53-independent death. It is able to activate Bax [70] and antagonize the function of antiapoptotic members of the Bcl-2 family [71]. Under basal conditions, PUMA is expressed in very small amounts, but is rapidly induced by various forms of stressors, including altered redox status. Its expression could be regulated by various transcription factors that respond to toxic stimuli [71]. The PUMA gene promoter contains binding sites for several transcription factors in addition to p53 (such as p73, c-Myc, FoxO3A, CHOP, E2F1, and AP-1), which could be differentially activated in different forms of cellular stress [72]. This probably may explain our results showing prominent copper-induced upregulation of PUMA together with unchanged p53 levels. Cotreatment with quercetin partially prevented PUMA induction, indicating that the suppression of PUMA activation could be the underlying mechanism of the observed neuroprotective action of quercetin in P19 neurons.

The role of NME1 in oxidative stress response has been recently emerging. This enzyme is mostly known for its nucleoside diphosphate kinase activity, although it also may exert many functions within the cell nucleus as well. Recent data indicate that DNA-damaging agents induce the presence of NME1 in the nucleus where it may regulate gene transcription acting as a transcription factor, or it may participate in the repair of DNA strand breaks [44]. Furthermore, NME1 overexpression promoted the survival of primary rat cortical neurons during excitotoxicity, hydrogen peroxide-induced oxidative stress, and oxygen-glucose deprivation [73]. NME1 was also secreted extracellularly in an in vitro model of traumatic brain injury which also might indicate its neuroprotective and regenerative function [74]. In line with these findings, NME1 expression was upregulated in quercetin-treated P19 neurons, suggesting its important role in promoting neuronal survival in copper-induced oxidative stress. Of note, it has been shown that NME1 may modulate Akt and ERK signalling pathways [75].

Growing evidence indicates that flavonoids exert neuroprotective effects by modulating various signalling cascades [18, 19]. We have previously shown that quercetin promotes the survival of P19 neurons in hydrogen peroxide-induced oxidative stress by modulating Akt and ERK1/2 signalling [26]. Similarly, pharmacological inhibition of PI3K/Akt and ERK1/2 pathways prevents the beneficial effects of quercetin on copper-induced neuronal death. Signal transduction through the PI3K/Akt and ERK1/2 pathways contributes to many aspects of neuronal functioning, and both pathways are considered as potential therapeutic targets in neurodegeneration [76, 77]. It has been shown that quercetin may induce the expression of the brain-derived neurotrophic factor (BDNF) which in turn activates the ERK and PI3K pathways [78]. Potential targets, as well as underlying mechanisms, that possibly determine the net survival of P19 neurons following exposure to quercetin and copper, are represented in Figure 7.

5. Conclusions

We observed a neuroprotective effect at a particular concentration of quercetin in modest oxidative stress conditions induced by exposure to divalent copper ions. In addition to antioxidative activities, this effect is mediated through the Akt and ERK signalling cascades. Quercetin reduces the increase in PUMA expression and upregulates NME1, which ultimately prevents the stimulation of caspase-3/7 activity and chromatin condensation. As such, quercetin and other flavonoids acting as modulators of Akt and ERK signalling pathways represent promising therapeutic approaches to alleviate the consequences of mild copper-induced oxidative stress.

Data Availability

The data used to support the findings are available upon request from the corresponding author.

Conflicts of Interest

The authors declare that there is no conflict of interest regarding the publication of this paper.

Acknowledgments

This work was funded by the Croatian Science Foundation grants IP-2014-09-9730, IP-11-2013-1615, and IP-2019-04-3584, the Croatian Ministry of Science, Education and Sports project 098-0000000-2448, the Catholic University of Croatia grant HKS-2018-2, the Scientific Center of Excellence for Basic, Clinical and Translational Neuroscience CoRE-NEURO (“Experimental and clinical research of hypoxic-ischemic damage in perinatal and adult brain”; GA KK01.1.1.01.0007 funded by the European Union through the European Regional Development Fund), and in part by NIH grant AG005138.

Supplementary Materials

Figure S1: differentiation of P19 neuronal cells. Immunofluorescence staining against β-III tubulin demonstrates complete neuronal differentiation. (Supplementary Materials)

References

  1. L. Gan, M. R. Cookson, L. Petrucelli, and A. R. la Spada, “Converging pathways in neurodegeneration, from genetics to mechanisms,” Nature Neuroscience, vol. 21, no. 10, pp. 1300–1309, 2018. View at: Publisher Site | Google Scholar
  2. I. Figueira, R. Menezes, D. Macedo, I. Costa, and C. N. dos Santos, “Polyphenols beyond barriers: a glimpse into the brain,” Current Neuropharmacology, vol. 15, no. 4, pp. 562–594, 2017. View at: Publisher Site | Google Scholar
  3. G. H. Kim, J. E. Kim, S. J. Rhie, and S. Yoon, “The role of oxidative stress in neurodegenerative diseases,” Experimental Neurobiology, vol. 24, no. 4, pp. 325–340, 2015. View at: Publisher Site | Google Scholar
  4. Z. Liu, T. Zhou, A. C. Ziegler, P. Dimitrion, and L. Zuo, “Oxidative stress in neurodegenerative diseases: from molecular mechanisms to clinical applications,” Oxidative Medicine and Cellular Longevity, vol. 2017, Article ID 2525967, 11 pages, 2017. View at: Publisher Site | Google Scholar
  5. J. N. Cobley, M. L. Fiorello, and D. M. Bailey, “13 reasons why the brain is susceptible to oxidative stress,” Redox Biology, vol. 15, pp. 490–503, 2018. View at: Publisher Site | Google Scholar
  6. L. M. Gaetke and C. K. Chow, “Copper toxicity, oxidative stress, and antioxidant nutrients,” Toxicology, vol. 189, no. 1-2, pp. 147–163, 2003. View at: Publisher Site | Google Scholar
  7. C. M. Ackerman and C. J. Chang, “Copper signaling in the brain and beyond,” The Journal of Biological Chemistry, vol. 293, no. 13, pp. 4628–4635, 2018. View at: Publisher Site | Google Scholar
  8. L. M. Gaetke, H. S. Chow-Johnson, and C. K. Chow, “Copper: toxicological relevance and mechanisms,” Archives of Toxicology, vol. 88, no. 11, pp. 1929–1938, 2014. View at: Publisher Site | Google Scholar
  9. C. Garza-Lombó, Y. Posadas, L. Quintanar, M. E. Gonsebatt, and R. Franco, “Neurotoxicity linked to dysfunctional metal ion homeostasis and xenobiotic metal exposure: redox signaling and oxidative stress,” Antioxidants & Redox Signaling, vol. 28, no. 18, pp. 1669–1703, 2018. View at: Publisher Site | Google Scholar
  10. F. Cioffi, R. H. I. Adam, and K. Broersen, “Molecular mechanisms and genetics of oxidative stress in Alzheimer’s disease,” Journal of Alzheimer’s Disease, vol. 72, no. 4, pp. 981–1017, 2019. View at: Publisher Site | Google Scholar
  11. R. Squitti, D. Lupoi, P. Pasqualetti et al., “Elevation of serum copper levels in Alzheimer’s disease,” Neurology, vol. 59, no. 8, pp. 1153–1161, 2002. View at: Publisher Site | Google Scholar
  12. M. Ventriglia, S. Bucossi, V. Panetta, and R. Squitti, “Copper in Alzheimer’s disease: a meta-analysis of serum, plasma, and cerebrospinal fluid studies,” Journal of Alzheimer's Disease, vol. 30, no. 4, pp. 981–984, 2012. View at: Publisher Site | Google Scholar
  13. S. Rivera-Mancía, I. Pérez-Neri, C. Ríos, L. Tristán-López, L. Rivera-Espinosa, and S. Montes, “The transition metals copper and iron in neurodegenerative diseases,” Chemico-Biological Interactions, vol. 186, no. 2, pp. 184–199, 2010. View at: Publisher Site | Google Scholar
  14. P. Faller, “Copper and zinc binding to amyloid-beta: coordination, dynamics, aggregation, reactivity and metal-ion transfer,” Chembiochem, vol. 10, no. 18, pp. 2837–2845, 2009. View at: Publisher Site | Google Scholar
  15. G. Grasso, A. M. Santoro, V. Lanza et al., “The double faced role of copper in Aβ homeostasis: a survey on the interrelationship between metal dyshomeostasis, UPS functioning and autophagy in neurodegeneration,” Coordination Chemistry Reviews, vol. 347, pp. 1–22, 2017. View at: Publisher Site | Google Scholar
  16. A. Kim, S. Lim, and Y. Kim, “Metal ion effects on Aβ and tau aggregation,” International Journal of Molecular Sciences, vol. 19, no. 1, p. 128, 2018. View at: Publisher Site | Google Scholar
  17. X. Wang, D. Moualla, J. A. Wright, and D. R. Brown, “Copper binding regulates intracellular alpha-synuclein localisation, aggregation and toxicity,” Journal of Neurochemistry, vol. 113, no. 3, pp. 704–714, 2010. View at: Publisher Site | Google Scholar
  18. N. A. Kelsey, H. M. Wilkins, and D. A. Linseman, “Nutraceutical antioxidants as novel neuroprotective agents,” Molecules, vol. 15, no. 11, pp. 7792–7814, 2010. View at: Publisher Site | Google Scholar
  19. D. Vauzour, K. Vafeiadou, A. Rodriguez-Mateos, C. Rendeiro, and J. P. E. Spencer, “The neuroprotective potential of flavonoids: a multiplicity of effects,” Genes & Nutrition, vol. 3, no. 3-4, pp. 115–126, 2008. View at: Publisher Site | Google Scholar
  20. S. Kumar and A. K. Pandey, “Chemistry and biological activities of flavonoids: an overview,” The Scientific World Journal, vol. 2013, 16 pages, 2013. View at: Publisher Site | Google Scholar
  21. M. Říha, J. Karlíčková, T. Filipský et al., “In vitro evaluation of copper-chelating properties of flavonoids,” RSC Advances, vol. 4, no. 62, pp. 32628–32638, 2014. View at: Publisher Site | Google Scholar
  22. P. Maher, “The potential of flavonoids for the treatment of neurodegenerative diseases,” International Journal of Molecular Sciences, vol. 20, no. 12, p. 3056, 2019. View at: Publisher Site | Google Scholar
  23. A. W. Boots, G. R. Haenen, and A. Bast, “Health effects of quercetin: from antioxidant to nutraceutical,” European Journal of Pharmacology, vol. 585, no. 2-3, pp. 325–337, 2008. View at: Publisher Site | Google Scholar
  24. A. Amić, B. Lučić, V. Stepanić et al., “Free radical scavenging potency of quercetin catecholic colonic metabolites: thermodynamics of 2H+/2e- processes,” Food Chemistry, vol. 218, pp. 144–151, 2017. View at: Publisher Site | Google Scholar
  25. M. Jazvinšćak Jembrek, L. Vuković, J. Puhović, J. Erhardt, and N. Oršolić, “Neuroprotective effect of quercetin against hydrogen peroxide-induced oxidative injury in P19 neurons,” Journal of Molecular Neuroscience, vol. 47, no. 2, pp. 286–299, 2012. View at: Publisher Site | Google Scholar
  26. M. Jazvinšćak Jembrek, J. Vlainić, V. Čadež, and S. Šegota, “Atomic force microscopy reveals new biophysical markers for monitoring subcellular changes in oxidative injury: neuroprotective effects of quercetin at the nanoscale,” PLoS One, vol. 13, no. 10, p. e0200119, 2018. View at: Publisher Site | Google Scholar
  27. H. L. Tseng, C. J. Li, L. H. Huang et al., “Quercetin 3-O-methyl ether protects FL83B cells from copper induced oxidative stress through the PI3K/Akt and MAPK/Erk pathway,” Toxicology and Applied Pharmacology, vol. 264, no. 1, pp. 104–113, 2012. View at: Publisher Site | Google Scholar
  28. L. G. Costa, J. M. Garrick, P. J. Roquè, and C. Pellacani, “Mechanisms of neuroprotection by quercetin: counteracting oxidative stress and more,” Oxidative Medicine and Cellular Longevity, vol. 2016, 10 pages, 2016. View at: Publisher Site | Google Scholar
  29. V. Radovanović, J. Vlainić, N. Hanžić et al., “Neurotoxic effect of ethanolic extract of propolis in the presence of copper ions is mediated through enhanced production of ROS and stimulation of caspase-3/7 activity,” Toxins, vol. 11, no. 5, p. 273, 2019. View at: Publisher Site | Google Scholar
  30. S. B. Bukhari, S. Memon, M. Mahroof-Tahir, and M. I. Bhanger, “Synthesis, characterization and antioxidant activity copper-quercetin complex,” Spectroscopy, vol. 71, no. 5, pp. 1901–1906, 2009. View at: Publisher Site | Google Scholar
  31. C. Park, H. S. So, C. H. Shin et al., “Quercetin protects the hydrogen peroxide-induced apoptosis via inhibition of mitochondrial dysfunction in H9c2 cardiomyoblast cells,” Biochemical Pharmacology, vol. 66, no. 7, pp. 1287–1295, 2003. View at: Publisher Site | Google Scholar
  32. A. Rauf, M. Imran, I. A. Khan et al., “Anticancer potential of quercetin: a comprehensive review,” Phytotherapy Research, vol. 32, no. 11, pp. 2109–2130, 2018. View at: Publisher Site | Google Scholar
  33. A. Robaszkiewicz, A. Balcerczyk, and G. Bartosz, “Antioxidative and prooxidative effects of quercetin on A549 cells,” Cell Biology International, vol. 31, no. 10, pp. 1245–1250, 2007. View at: Publisher Site | Google Scholar
  34. A. Pȩkal, M. Biesaga, and K. Pyrzynska, “Interaction of quercetin with copper ions: complexation, oxidation and reactivity towards radicals,” Biometals, vol. 24, no. 1, pp. 41–49, 2011. View at: Publisher Site | Google Scholar
  35. L. Mira, M. T. Fernandez, M. Santos, R. Rocha, M. H. Florêncio, and K. R. Jennings, “Interactions of flavonoids with iron and copper ions: a mechanism for their antioxidant activity,” Free Radical Research, vol. 36, no. 11, pp. 1199–1208, 2009. View at: Publisher Site | Google Scholar
  36. H. El Hajji, E. Nkhili, V. Tomao, and O. Dangles, “Interactions of quercetin with iron and copper ions: complexation and autoxidation,” Free Radical Research, vol. 40, no. 3, pp. 303–320, 2009. View at: Publisher Site | Google Scholar
  37. A. C. Grobin, J. R. Inglefield, R. D. Schwartz-Bloom, L. L. Devaud, and A. L. Morrow, “Fluorescence imaging of GABAA receptor-mediated intracellular [Cl] in P19-N cells reveals unique pharmacological properties,” Brain Research, vol. 827, no. 1-2, pp. 1–11, 1999. View at: Publisher Site | Google Scholar
  38. M. Jazvinšćak Jembrek, A. Čipak Gašparović, L. Vuković, J. Vlainić, N. Žarković, and N. Oršolić, “Quercetin supplementation: insight into the potentially harmful outcomes of neurodegenerative prevention,” Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 385, no. 12, pp. 1185–1197, 2012. View at: Publisher Site | Google Scholar
  39. H. Wang and J. A. Joseph, “Quantifying cellular oxidative stress by dichlorofluorescein assay using microplate reader,” Free Radical Biology & Medicine, vol. 27, no. 5-6, pp. 612–616, 1999. View at: Publisher Site | Google Scholar
  40. M. Jazvinšćak Jembrek, J. Vlainić, V. Radovanović, J. Erhardt, and N. Oršolić, “Effects of copper overload in P19 neurons: impairment of glutathione redox homeostasis and crosstalk between caspase and calpain protease systems in ROS-induced apoptosis,” Biometals, vol. 27, no. 6, pp. 1303–1322, 2014. View at: Publisher Site | Google Scholar
  41. S. Elmore, “Apoptosis: a review of programmed cell death,” Toxicologic Pathology, vol. 35, no. 4, pp. 495–516, 2016. View at: Publisher Site | Google Scholar
  42. J. B. White, J. Beckford, S. Yadegarynia, N. Ngo, T. Lialiutska, and M. d’Alarcao, “Some natural flavonoids are competitive inhibitors of caspase-1, -3, and -7 despite their cellular toxicity,” Food Chemistry, vol. 131, no. 4, pp. 1453–1459, 2012. View at: Publisher Site | Google Scholar
  43. D. B. Wang, C. Kinoshita, Y. Kinoshita, and R. S. Morrison, “p53 and mitochondrial function in neurons,” Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, vol. 1842, no. 8, pp. 1186–1197, 2014. View at: Publisher Site | Google Scholar
  44. G. S. Puts, M. K. Leonard, N. V. Pamidimukkala, D. E. Snyder, and D. M. Kaetzel, “Nuclear functions of NME proteins,” Laboratory Investigation, vol. 98, no. 2, pp. 211–218, 2018. View at: Publisher Site | Google Scholar
  45. J. Bain, L. Plater, M. Elliott et al., “The selectivity of protein kinase inhibitors: a further update,” The Biochemical Journal, vol. 408, no. 3, pp. 297–315, 2007. View at: Publisher Site | Google Scholar
  46. K. A. Jellinger, “Recent advances in our understanding of neurodegeneration,” Journal of Neural Transmission, vol. 116, no. 9, pp. 1111–1162, 2009. View at: Publisher Site | Google Scholar
  47. K. Jomova and M. Valko, “Advances in metal-induced oxidative stress and human disease,” Toxicology, vol. 283, no. 2-3, pp. 65–87, 2011. View at: Publisher Site | Google Scholar
  48. A. Singh, R. Kukreti, L. Saso, and S. Kukreti, “Oxidative stress: a key modulator in neurodegenerative diseases,” Molecules, vol. 24, no. 8, p. 1583, 2019. View at: Publisher Site | Google Scholar
  49. M. Simunkova, S. H. Alwasel, I. M. Alhazza et al., “Management of oxidative stress and other pathologies in Alzheimer’s disease,” Archives of Toxicology, vol. 93, no. 9, pp. 2491–2513, 2019. View at: Publisher Site | Google Scholar
  50. T. Akaishi, T. Morimoto, M. Shibao et al., “Structural requirements for the flavonoid fisetin in inhibiting fibril formation of amyloid beta protein,” Neuroscience Letters, vol. 444, no. 3, pp. 280–285, 2008. View at: Publisher Site | Google Scholar
  51. F. Yin, J. Liu, X. Ji, Y. Wang, J. Zidichouski, and J. Zhang, “Silibinin: a novel inhibitor of Aβ aggregation,” Neurochemistry International, vol. 58, no. 3, pp. 399–403, 2011. View at: Publisher Site | Google Scholar
  52. S. Mandel and M. B. Youdim, “Catechin polyphenols: neurodegeneration and neuroprotection in neurodegenerative diseases,” Free Radical Biology & Medicine, vol. 37, no. 3, pp. 304–317, 2004. View at: Publisher Site | Google Scholar
  53. J. Chakraborty, U. Rajamma, N. Jana, and K. P. Mohanakumar, “Quercetin improves the activity of the ubiquitin-proteasomal system in 150Q mutated huntingtin-expressing cells but exerts detrimental effects on neuronal survivability,” Journal of Neuroscience Research, vol. 93, no. 10, pp. 1581–1591, 2015. View at: Publisher Site | Google Scholar
  54. M. Ayaz, A. Sadiq, M. Junaid et al., “Flavonoids as prospective neuroprotectants and their therapeutic propensity in aging associated neurological disorders,” Frontiers in Aging Neuroscience, vol. 11, 2019. View at: Publisher Site | Google Scholar
  55. N. R. Perron, C. R. García, J. R. Pinzón, M. N. Chaur, and J. L. Brumaghim, “Antioxidant and prooxidant effects of polyphenol compounds on copper-mediated DNA damage,” Journal of Inorganic Biochemistry, vol. 105, no. 5, pp. 745–753, 2011. View at: Publisher Site | Google Scholar
  56. G. H. Heeba and M. E. Mahmoud, “Dual effects of quercetin in doxorubicin-induced nephrotoxicity in rats and its modulation of the cytotoxic activity of doxorubicin on human carcinoma cells,” Environmental Toxicology, vol. 31, no. 5, pp. 624–636, 2014. View at: Publisher Site | Google Scholar
  57. A. R. White, G. Multhaup, F. Maher et al., “The Alzheimer’s disease amyloid precursor protein modulates copper-induced toxicity and oxidative stress in primary neuronal cultures,” The Journal of Neuroscience, vol. 19, no. 21, pp. 9170–9179, 1999. View at: Publisher Site | Google Scholar
  58. R. Giampietro, F. Spinelli, M. Contino, and N. A. Colabufo, “The pivotal role of copper in neurodegeneration: a new strategy for the therapy of neurodegenerative disorders,” Molecular Pharmaceutics, vol. 15, no. 3, pp. 808–820, 2018. View at: Publisher Site | Google Scholar
  59. N. Yamashita, H. Tanemura, and S. Kawanishi, “Mechanism of oxidative DNA damage induced by quercetin in the presence of Cu(II),” Mutation Research, vol. 425, no. 1, pp. 107–115, 1999. View at: Publisher Site | Google Scholar
  60. T. Jun, Z. Liancai, and W. Bochu, “Effects of quercetin on DNA damage induced by copper ion,” International Journal of Pharmacology, vol. 3, no. 1, pp. 19–26, 2007. View at: Publisher Site | Google Scholar
  61. P. Filipe, J. Haigle, J. N. Silva et al., “Anti- and pro-oxidant effects of quercetin in copper-induced low density lipoprotein oxidation: quercetin as an effective antioxidant against pro-oxidant effects of urate,” European Journal of Biochemistry, vol. 271, no. 10, pp. 1991–1999, 2004. View at: Publisher Site | Google Scholar
  62. Y. Iwasaki, T. Hirasawa, Y. Maruyama et al., “Effect of interaction between phenolic compounds and copper ion on antioxidant and pro-oxidant activities,” Toxicology in Vitro, vol. 25, no. 7, pp. 1320–1327, 2011. View at: Publisher Site | Google Scholar
  63. J. Terao, K. Murota, and Y. Kawai, “Conjugated quercetin glucuronides as bioactive metabolites and precursors of aglycone in vivo,” Food & Function, vol. 2, no. 1, pp. 11–17, 2011. View at: Publisher Site | Google Scholar
  64. A. W. Boots, H. Li, R. P. F. Schins et al., “The quercetin paradox,” Toxicology and Applied Pharmacology, vol. 222, no. 1, pp. 89–96, 2007. View at: Publisher Site | Google Scholar
  65. T. F. Beckhauser, J. Francis-Oliveira, and R. De Pasquale, “Reactive oxygen species: physiological and physiopathological effects on synaptic plasticity,” Journal of Experimental Neuroscience, vol. 10s1, pp. JEN.S39887–JEN.S39848, 2016. View at: Publisher Site | Google Scholar
  66. M. Fricker, A. M. Tolkovsky, V. Borutaite, M. Coleman, and G. C. Brown, “Neuronal cell death,” Physiological Reviews, vol. 98, no. 2, pp. 813–880, 2018. View at: Publisher Site | Google Scholar
  67. D. Steckley, M. Karajgikar, L. B. Dale et al., “Puma is a dominant regulator of oxidative stress induced Bax activation and neuronal apoptosis,” The Journal of Neuroscience, vol. 27, no. 47, pp. 12989–12999, 2007. View at: Publisher Site | Google Scholar
  68. L. P. Zhao, C. Ji, P. H. Lu, C. Li, B. Xu, and H. Gao, “Oxygen glucose deprivation (OGD)/re-oxygenation-induced in vitro neuronal cell death involves mitochondrial cyclophilin-D/P53 signaling axis,” Neurochemical Research, vol. 38, no. 4, pp. 705–713, 2013. View at: Publisher Site | Google Scholar
  69. A. V. Vaseva, N. D. Marchenko, K. Ji, S. E. Tsirka, S. Holzmann, and U. M. Moll, “p53 opens the mitochondrial permeability transition pore to trigger necrosis,” Cell, vol. 149, no. 7, pp. 1536–1548, 2012. View at: Publisher Site | Google Scholar
  70. L. Vela, O. Gonzalo, J. Naval, and I. Marzo, “Direct interaction of bax and bak proteins with Bcl-2 homology domain 3 (BH3)-only proteins in living cells revealed by fluorescence complementation,” The Journal of Biological Chemistry, vol. 288, no. 7, pp. 4935–4946, 2013. View at: Publisher Site | Google Scholar
  71. J. Yu and L. Zhang, “PUMA, a potent killer with or without p53,” Oncogene, vol. 27, no. S1, pp. S71–S83, 2008. View at: Publisher Site | Google Scholar
  72. P. Hikisz and Z. M. Kiliańska, “Puma, a critical mediator of cell death—one decade on from its discovery,” Cellular & Molecular Biology Letters, vol. 17, no. 4, pp. 646–669, 2012. View at: Publisher Site | Google Scholar
  73. J. Teoh, S. Boulos, J. Chieng, N. W. Knuckey, and B. P. Meloni, “Erythropoietin increases neuronal NDPKA expression, and NDPKA up-regulation as well as exogenous application protects cortical neurons from in vitro ischemia-related insults,” Cellular and Molecular Neurobiology, vol. 34, no. 3, pp. 379–392, 2014. View at: Publisher Site | Google Scholar
  74. P. Romani, M. Ignesti, G. Gargiulo, T. Hsu, and V. Cavaliere, “Extracellular NME proteins: a player or a bystander?” Laboratory Investigation, vol. 98, no. 2, pp. 248–257, 2018. View at: Publisher Site | Google Scholar
  75. M. Q. Li, J. Shao, Y. H. Meng et al., “NME1 suppression promotes growth, adhesion and implantation of endometrial stromal cells via Akt and MAPK/Erk1/2 signal pathways in the endometriotic milieu,” Human Reproduction, vol. 28, no. 10, pp. 2822–2831, 2013. View at: Publisher Site | Google Scholar
  76. S. Subramaniam and K. Unsicker, “ERK and cell death: ERK1/2 in neuronal death,” The FEBS Journal, vol. 277, no. 1, pp. 22–29, 2010. View at: Publisher Site | Google Scholar
  77. K. Sánchez-Alegría, M. Flores-León, E. Avila-Muñoz, N. Rodríguez-Corona, and C. Arias, “PI3K signaling in neurons: a central node for the control of multiple functions,” International Journal of Molecular Sciences, vol. 19, no. 12, p. 3725, 2018. View at: Publisher Site | Google Scholar
  78. T. Numakawa, H. Odaka, and N. Adachi, “Actions of brain-derived neurotrophin factor in the neurogenesis and neuronal function, and its involvement in the pathophysiology of brain diseases,” International Journal of Molecular Sciences, vol. 19, no. 11, p. 3650, 2018. View at: Publisher Site | Google Scholar

Copyright © 2020 Klara Zubčić et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder
Views489
Downloads385
Citations

Related articles